Leanbio

Leanbio is a Contract Development and Manufacturing Organization (CDMO) specializing in the development and manufacture of biopharmaceutical products, including biologics, biosimilars, and new biological entities. Founded in 2014 by Dr. Andreu Soldevila and Dr. Albert Font, the company is headquartered at the Barcelona Science Park. Leanbio employs a lean production and Quality by Design (QbD) approach to maximize success while reducing time to market, costs, and risks for its clients.

The company offers comprehensive services covering the entire lifecycle of biological products, from initial stages to advanced phases. These services include strain and cell line development, analytical development, manufacturing process development, formulation, and final manufacturing. Leanbio utilizes proprietary technology platforms for various expression systems, including E. coli, Bacillus, P. pastoris, and CHO cells, enabling the production of recombinant proteins, antibodies, plasmid DNA, and messenger RNA for advanced therapies.

In December 2023, Leanbio announced an additional EUR 20 million investment in its new manufacturing facility under construction in Sant Quirze del Vallès, Barcelona. The 3,500m2 plant, set to be operational in 2025, will feature three GMP-certified production lines for mammalian cells, microbial cultures, and gene therapy molecules. This expansion aims to meet the growing demand for global projects in biologics manufacturing.

Leanbio's business model focuses on a flexible and integrated approach, tailoring biotechnological product development and manufacturing to client needs while adhering to high-quality industry standards. The company's expertise extends from milligram to kilogram-scale production, supporting non-clinical, clinical development, and routine manufacturing.